drugset / Trial / NCT04342572

Intra-arterial Chemotherapy for Retinoblastoma

NCT04342572

Phase 1 Completed 5 enrolled Washington University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

Children with retinoblastoma who may benefit from intra-arterial chemotherapy will receive up to 3 doses of melphalan and will be assessed for feasibility, toxicity, and response.

Timeline

Start
2020-08-11
Primary completion
2023-01-04
Completion
2025-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Melphalan Small molecule Other

Indications